Success at inaugral Research Impact Awards

Posted by mlb43 at Jul 03, 2017 12:55 PM |
Profs. Andy Wardlaw and Chris Brightling win Best Societal Impact (achieved) award
Success at inaugral Research Impact Awards

The team with their award

Congratulations to our Respiratory colleagues who were successful at the inaugural Research Impact awards ceremony held at Stanford Court on 27 June 2017. The award was Best Societal Impact (achieved).

Flare-ups or exacerbations are a particular feature of severe asthma, and require people to take time off work, come into hospital and occasionally cause death - about 1,000 cases a year in the UK. It was long thought that the two patterns of asthma (day-to-day symptoms and exacerbations), were inextricably linked. The great insight of the Leicester respiratory group was that these two processes, while closely connected, could occur independently.

A close, collaborative relationship with GlaxoSmithKline led to the study of new drug mepolizumab in severe, exacerbation prone, eosinophilic asthma. This study was successful in demonstrating about a 50% reduction in severe exacerbations, eventually leading GSK to obtain a global licence for mepolizumab (as NucalaTM), in late 2015. In December 2016, NICE approved the treatment for severe eosinophilic asthma.

Share this page: